Trust & governance
About Microdose GLP One
Our mission, scope, and what we do and do not do.
Microdose GLP One is an independent consumer resource that defines the poorly-standardized topic of GLP-1 microdosing, separates marketing terminology from medical evidence, normalizes provider costs, verifies pharmacies, and states what remains unknown. It does not sell medication, prescribe, or recommend a dose.
Mission
We help U.S. consumers understand GLP-1 microdosing and lower-dose strategies accurately. The wellness market uses 'microdose' loosely; we hold a definition firewall that names the exact dose concept on every page and refuses to publish universal dosing schedules.
Scope
We cover semaglutide and tirzepatide microdosing, lower-dose and maintenance strategies, off-ramping, providers, compounded formulations, cost, safety, pharmacy verification, and the clinical research. We separate FDA-approved products from compounded products throughout.
What we do not do
We do not sell or prescribe medication, recommend a dose, provide a syringe-unit calculator or titration chart, or claim a lower dose is safer or equally effective without exact evidence. Provider reviews, rankings, and comparisons stay unpublished until first-party verified.
Contact and corrections
Reach us through the contact page; report errors via the corrections policy.
Frequently asked questions
Is Microdose GLP One a medical provider?
No. It is an independent publication, not a healthcare provider, pharmacy, or regulator, and not a substitute for professional medical advice.
Do you sell medication?
No. We publish research and comparisons and do not sell, prescribe, or dispense medication.
Publisher: Microdose GLP One. Compounded medications are not FDA approved. Questions or corrections: see the corrections policy and contact page.